Dr. Christopher Cannon
Add to your Care-Team
Dr. Christopher Cannon
Dr. Christopher Cannon
I specialize in
I have been in practice
My answers and insights have
Helped 20 people
Here are kind words from others
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I am located at
Seattle , WA 98122
Accepted Insurance Plans
First Choice Health
Great West Healthcare
Labor & Industries
National Provider Network
Premera Blue Cross
Three Rivers Provider Network
Uniform Medical Plan
I was educated and trained at
Medical / Graduate School
University of Washington School of Medicine, Seattle
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
J. Thromb. Thrombolysis., Dec (2012)
The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data.
Clin Cardiol., 35(12):714-7 (2012)
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
J. Lipid Res., Nov (2012)
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.
Eur. Heart J., Nov (2012)
Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction.
J. Am. Coll. Cardiol., Nov (2012)
Circadian Variation in Patient Characteristics and Outcomes in ST-Segment Elevation Myocardial Infarction.
Chronobiol. Int., Dec;29(10):1390-6 (2012)
Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the american heart association get with the guidelines coronary artery disease program.
J Am Heart Assoc., Aug;1(4):e001206 (2012)
Î²-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
JAMA., Oct;308(13):1340-9 (2012)
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
J. Am. Coll. Cardiol., Oct;60(17):1623-30 (2012)
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Circ Cardiovasc Qual Outcomes., Sep;5(5):680-8 (2012)
Guideline adherence after ST-segment elevation versus non-ST segment elevation myocardial infarction.
Circ Cardiovasc Qual Outcomes., Sep;5(5):654-61 (2012)
Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction.
Am. J. Med., Aug (2012)
The controversies of statin therapy: weighing the evidence.
J. Am. Coll. Cardiol., Sep;60(10):875-81 (2012)
Danger ahead: watch out for indirect comparisons!
J. Am. Coll. Cardiol., Aug;60(8):747-8 (2012)
An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials.
J. Am. Coll. Cardiol., Jul;60(2):106-11 (2012)
Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins.
Rev Cardiovasc Med., 13(1):e48-51 (2012)
Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines.
Clin Cardiol., 35(7):396-403 (2012)
Age and gender differences in quality of care and outcomes for patients with ST-segment elevation myocardial infarction.
Am. J. Med., Oct;125(10):1000-9 (2012)
Reperfusion strategies and quality of care in 5339 patients age 80 years or older presenting with ST-elevation myocardial infarction: analysis from get with the guidelines-coronary artery disease.
Clin Cardiol., Oct;35(10):632-40 (2012)
Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program.
Clin Cardiol., Sep;35(9):541-7 (2012)
Aspirin resistance: current status and role of tailored therapy.
Clin Cardiol., Nov;35(11):673-80 (2012)
Physiology. COX-2 inhibitors and cardiovascular risk.
Science., Jun;336(6087):1386-7 (2012)
A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology.
Clin Cardiol., 35(7):404-9 (2012)
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes.
Circulation., Jul;126(1):65-75 (2012)
A new approach to managing the 'statin-intolerant' patient?
Eur. Heart J., May;33(9):1040-3 (2012)
Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations.
Am. J. Cardiol., Jul;110(2):307-13 (2012)
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
J. Thromb. Thrombolysis., Aug;34(2):222-8 (2012)
Triglycerides: how much credit do they deserve?
Med. Clin. North Am., Jan;96(1):39-55 (2012)
Are continuing medical education activities effective in improving the competence and performance of clinicians? Evidence from activities for primary care clinicians who manage patients with acute coronary syndromes.
Crit Pathw Cardiol., Mar;11(1):1-9 (2012)
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial.
Circulation., Feb;125(8):978-86 (2012)
Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines-Coronary Artery Disease program.
Circ Cardiovasc Qual Outcomes., Jan;5(1):126-33 (2012)
Acute coronary syndromes in 2011: Walking the tightrope between efficacy and bleeding.
Nat Rev Cardiol., Feb;9(2):69-71 (2012)
Personalized therapy following drug-eluting stenting using platelet function testing and C-reactive protein.
J. Am. Coll. Cardiol., Dec;58(25):2640-1 (2011)
Statins and safety: can we finally be reassured?
Lancet., Dec;378(9808):1980-1 (2011)
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Clin. Chem., Jan;58(1):267-73 (2012)
High-density lipoprotein cholesterol as the Holy Grail.
JAMA., Nov;306(19):2153-5 (2011)
Take heart: a one-on-one peer-based strategy to improve acute coronary syndrome patient care.
Crit Pathw Cardiol., Dec;10(4):164-8 (2011)
Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association's Get With The Guidelines program.
Circ Cardiovasc Qual Outcomes., Nov;4(6):610-8 (2011)
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care?
J. Am. Coll. Cardiol., Oct;58(17):1760-5 (2011)
Results of a survey assessing provider beliefs of adherence barriers to antiplatelet medications.
Crit Pathw Cardiol., Sep;10(3):134-41 (2011)
Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
Crit Pathw Cardiol., Jun;10(2):84-6 (2011)
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi
Am. Heart J., Oct;162(4):620-626.e1 (2011)
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
Am. Heart J., Oct;162(4):613-619.e1 (2011)
Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
Mayo Clin. Proc., Oct;86(10):960-7 (2011)
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Am. J. Cardiol., Dec;108(11):1542-6 (2011)
Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs.
Cardiovasc Ther., Dec;30(6):342-350 (2012)
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Circulation., Sep;124(10):1132-7 (2011)
Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD).
Am. Heart J., Aug;162(2):283-290.e2 (2011)
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Eur. Heart J., Dec;32(23):2945-53 (2011)
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation., Aug;124(5):544-54 (2011)
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
JAMA., Jun;305(24):2556-64 (2011)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
BMJ., 342:d3527 (2011)
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Am. Heart J., Jun;161(6):1147-55.e1 (2011)
A report of quality improvement in the care of patients with acute coronary syndromes.
Crit Pathw Cardiol., Mar;10(1):29-34 (2011)
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
J. Am. Coll. Cardiol., May;57(19):1908-16 (2011)
New options for stroke prevention in atrial fibrillation.
Am J Manag Care., Nov;16(10 Suppl):S291-7 (2010)
An overview of stroke and the impact of atrial fibrillation.
Am J Manag Care., Nov;16(10 Suppl):S273-7 (2010)
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Circ Cardiovasc Qual Outcomes., May;4(3):328-36 (2011)
Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies.
Circulation., Apr;123(15):1622-32 (2011)
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
J. Rheumatol., Jun;38(6):1071-8 (2011)
Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry).
Am. J. Cardiol., May;107(10):1441-6 (2011)
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
JAMA., Mar;305(11):1097-105 (2011)
Myocardial infarction vaccine? Evidence supporting the influenza vaccine for secondary prevention.
Eur. Heart J., Jul;32(14):1701-3 (2011)
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG).
Am. Heart J., Feb;161(2):418-424.e1-3 (2011)
Clopidogrel: to test or not to test? That is the question--still.
Clin. Chem., May;57(5):659-61 (2011)
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Eur. Heart J., Jun;32(11):1390-7 (2011)
In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION RegistryÂ®-GWTGâ„¢.
Am. J. Cardiol., Apr;107(8):1136-43 (2011)
Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis.
J. Thromb. Thrombolysis., May;31(4):493-500 (2011)
Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care.
Circ Cardiovasc Qual Outcomes., Jan;4(1):129-35 (2011)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
J. Am. Coll. Cardiol., Feb;57(6):672-84 (2011)
Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: the acute coronary treatment and intervention outcomes network (ACTION) registry-get with the guidelines (GWTG) acute myocardial infarction mortality mode
Am. Heart J., Jan;161(1):113-122.e2 (2011)
Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
Am. Heart J., Dec;160(6):1130-6, 1136.e1-3 (2010)
Duration of dual antiplatelet therapy following percutaneous coronary intervention with drug-eluting stents: a review of recent evidence.
Crit Pathw Cardiol., Dec;9(4):203-6 (2010)
Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--G
JACC Cardiovasc Interv., Nov;3(11):1166-77 (2010)
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
N. Engl. J. Med., Dec;363(25):2406-15 (2010)
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Circulation., Nov;122(21):2131-41 (2010)
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Circulation., Nov;122(21):2142-51 (2010)
Cardiac rehabilitation. Cardiac rehabilitation reduces the long-term risk of death and cardiovascular complications.
Rev Cardiovasc Med., 11(3):e181-4 (2010)
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
JAMA., Oct;304(16):1821-30 (2010)
Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.
Arterioscler. Thromb. Vasc. Biol., Jan;31(1):203-10 (2011)
Could direct inhibition of inflammation be the "next big thing" in treating atherosclerosis?
Arterioscler. Thromb. Vasc. Biol., Nov;30(11):2081-3 (2010)
Prior aspirin use and outcomes in acute coronary syndromes.
J. Am. Coll. Cardiol., Oct;56(17):1376-85 (2010)
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
Am. Heart J., Oct;160(4):655-61 (2010)
Clopidogrel with or without omeprazole in coronary artery disease.
N. Engl. J. Med., Nov;363(20):1909-17 (2010)
Bleeding complications of unfractionated heparin.
Expert Opin Drug Saf., Jan;10(1):77-84 (2011)
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
J. Am. Coll. Cardiol., Oct;56(18):1456-62 (2010)
Late outcomes after carotid artery stenting versus carotid endarterectomy: insights from a propensity-matched analysis of the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
Circulation., Sep;122(11):1091-100 (2010)
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Circulation., Sep;122(11):1056-67 (2010)
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Crit Pathw Cardiol., Sep;9(3):156-9 (2010)
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis.
Crit Pathw Cardiol., Sep;9(3):116-25 (2010)
Performance achievement award program for Get With The Guidelines--Coronary Artery Disease is associated with global and sustained improvement in cardiac care for patients hospitalized with an acute myocardial infarction.
Crit Pathw Cardiol., Sep;9(3):103-12 (2010)
The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care.
Heart., Nov;96(22):1798-802 (2010)
News and views from the literature. Antiplatelet therapy. Ticagrelor in acute coronary syndrome: a new frontier in platelet inhibition.
Rev Cardiovasc Med., 11(2):117-20 (2010)
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Am. J. Cardiol., Aug;106(4):451-6 (2010)
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.
J. Am. Coll. Cardiol., Jul;56(4):254-63 (2010)
Association of insurance status with inpatient treatment for coronary artery disease: findings from the Get With the Guidelines program.
Am. Heart J., Jun;159(6):1026-36 (2010)
Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLAR
Am. Heart J., Jun;159(6):964-971.e1 (2010)
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
Eur. Heart J., Aug;31(16):1993-2005 (2010)
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.
Crit Pathw Cardiol., Jun;9(2):55-81 (2010)
Patent foramen ovale. Incidental patent foramen ovale during cardiothoracic surgery: to repair or not to repair?
Rev Cardiovasc Med., 11(1):53-6 (2010)
Dr. Christopher Cannon M